Helping dogs
live longer,
healthier lives
Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs.
Stay connected
Jumbo
Age 2
Our team
153
Papers published
56
Clinical drug programs worked on
192
Years of research
61%
Women
Leadership team
Celine Halioua
Founder & CEO
Sudharika Gogna
Chief Operating Officer
Cheryl Heinonen
Chief People & Communications Officer
Hubert Chen
Chief Development Officer
Karen Greenwood
SVP, Regulatory & Strategy
Dina Juarez-Salinas
VP, Preclinical Development
Stacy Ross
VP, Drug Development
Board of directors
Celine Halioua
Director
Founder & CEO
Kevin Zhang
Director
Partner, Bain Capital Ventures
Laura Deming
Director
Founder/GP, Longevity Fund
Blake Scholl
Director
Founder/CEO, Boom Supersonic
Linda Rhodes, DVM, PhD
Director
Former CEO & Chief Scientific Officer, Aratana Therapeutics
Dr. Stephen Betz
Board Observer
Founder/CSO, Crinetics Pharmaceuticals ($CRNX)
Josh Kopelman
Board Observer
Founder/GP, First Round Capital
Greg Rosen
Board Observer
Partner, Box Group
Wilbur
Age 4
Press
room
room
Loyal in the news
See all
Announcements
See allPress inquiries
Contact us at press@loyalfordogs.com
Interviews and podcasts
Backed by the best
Publications
April, 2024
McKenzie B, Peloquin M, Tovar A, Graves JL, Ratcliff E, Tucker K, Vo K, Greenwood K, Halioua-Haubold CL, Juarez-Salinas D. Feeding dogs a high-fat diet induces metabolic changes similar to natural aging, including dyslipidemia, hyperinsulinemia, and peripheral insulin resistance. AVMA. 2024 Apr 15. (published online ahead of print 2024).
February, 2023
Chen FL, Ullal TV, Graves JL, Ratcliff ER, Naka A, McKenzie B, Carttar TA, Super KM, Austriaco J, Weber SY, Vaughn J, LaCroix-Fralish ML. Evaluating instruments for assessing healthspan: a multi-center cross-sectional study on health-related quality of life (HRQL) and frailty in the companion dog. GeroScience. 2023 Feb 13.
June, 2022
McKenzie BA, Chen FL, LaCroix-Fralish ML. The phenotype of aging in the dog: how aging impacts the health and well-being of dogs and their caregivers. AVMA. 2022 Jun 1;260(9):963-70.
June, 2022
McKenzie BA. Comparative veterinary geroscience: mechanism of molecular, cellular, and tissue aging in humans, laboratory animal models, and companion dogs and cats. AJVR. 2022 Jun 1;83(6).
April, 2022
McKenzie BA, Chen FL, Gruen ME, Olby NJ. Canine Geriatric Syndrome: A Framework for Advancing Research in Veterinary Geroscience. Front. Vet. Sci. 2022 April 21;9:853743.
September, 2021
Chen FL, Zimmermann M, Hekman JP, Lord KA, Logan B, Russenberger J, et al. Advancing Genetic Selection and Behavioral Genomics of Working Dogs Through Collaborative Science. Front. Vet. Sci. 2021 Sept 6;8:662429.
Sky
Age 2
Our impact
Healthy aging and better quality of life
Aging is the ultimate risk factor for some of the most destructive and painful diseases. Instead of chasing the cascading symptoms of diseases associated with aging, our goal is to develop drugs that slow the rate of aging. By delaying the onset and reducing the impact of many age-related diseases, dogs can have more healthier years.
From reactive to preventive medicine
Most medicines today can be classified as “reactive medicines” — once you’re already sick, they are taken to relieve or reduce symptoms. Unfortunately, by the time symptoms develop permanent damage is often already done. We aim to develop medicines that prevent or delay the onset of age-related diseases.
Doing what’s rigorous and what’s right
Our work is intentional, thoughtful, and guided by respect for life. We take our responsibility to pets, pet owners and vets seriously. We are focused on helping dogs live longer, healthier lives.